RP
VRTX icon

Richard Pzena’s Vertex Pharmaceuticals VRTX Stock Holding History

Richard Pzena’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,905
Closed -$638K – 185
2021
Q4 		$638K Buy
+2,905
New +$565K ﹤0.01% 144

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Richard Pzena's VRTX Position: Q1 2022 in Review

Richard Pzena sold out of Vertex Pharmaceuticals (VRTX) in Q1 2022, closing a stake of 2,905 shares — an estimated $638K sold.

Richard Pzena first reported a position in VRTX in Q4 2021 and held it in 1 quarter. The position peaked at $638K in Q4 2021. 1,072 funds tracked by Wall St. Rank hold VRTX as of Q1 2022.

  • Richard Pzena reported no remaining Vertex Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Richard Pzena sold 2,905 Vertex Pharmaceuticals shares in Q1 2022, an estimated $638K.
  • Richard Pzena first reported a position in Vertex Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Richard Pzena's Vertex Pharmaceuticals position peaked at $638K in Q4 2021.
  • 1,072 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2022.

Based on Pzena Investment Management's 13F filing for Q1 2022, filed 6 May 2022.